Brief: Adaptimmune Enhances Its Pipeline Of Wholly Owned Cell Therapies For Cancer With Transfer Of Prame And Ny-Eso Target Programs From Gsk

Adaptimmune Therapeutics

25/10/2022 13:48

Oct 25 (Reuters) - Adaptimmune Therapeutics PLC
 ADAP.O :
    * ADAPTIMMUNE ENHANCES ITS PIPELINE OF WHOLLY OWNED CELL
THERAPIES
FOR CANCER WITH TRANSFER OF PRAME AND NY-ESO TARGET PROGRAMS
FROM GSK
    * ADAPTIMMUNE THERAPEUTICS PLC - CO GAINS FULL CONTROL OF
LATE-STAGE PRECLINICAL OPTIMIZED PRAME TCR; IND-READY IN 2023
    * ADAPTIMMUNE THERAPEUTICS PLC - GSK TO DELIVER DATA FROM
ONGOING
PHASE 2 TRIAL WITH LETE-CEL IN SARCOMA WITH FINAL READOUTS
EXPECTED IN LATE 2023
    * ADAPTIMMUNE -  ON OCT 24, GOT NOTICE OF TERMINATION OF
COLLABORATION AND LICENSE AGREEMENT WITH GLAXOSMITHKLINE
INTELLECTUAL PROPERTY DEVELOPMENT
    * ADAPTIMMUNE THERAPEUTICS PLC -  TERMS OF THE TRANSFER ARE
BEING
NEGOTIATED
    * ADAPTIMMUNE - PENDING DEAL  ON TRANSFER OF NY-ESO CELL
THERAPY
PROGRAM, GSK TO CONTINUE TO BE RESPONSIBLE FOR EXECUTION, COST
OF CLINICAL TRIALS
    * ADAPTIMMUNE THERAPEUTICS PLC - PRAME PROGRAM IS CURRENTLY
PRECLINICAL AND HAS NOT YET BEEN TRANSITIONED TO GSK
    * ADAPTIMMUNE THERAPEUTICS PLC - DEAL TERMINATION DOES NOT
TRIGGER
ANY PAYMENT OBLIGATIONS ON PART OF ADAPTIMMUNE

Further company coverage:  ADAP.O 
 ((Reuters.Briefs@thomsonreuters.com;;))